BRPI0507071A - derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase - Google Patents
derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinaseInfo
- Publication number
- BRPI0507071A BRPI0507071A BRPI0507071-6A BRPI0507071A BRPI0507071A BR PI0507071 A BRPI0507071 A BR PI0507071A BR PI0507071 A BRPI0507071 A BR PI0507071A BR PI0507071 A BRPI0507071 A BR PI0507071A
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidin
- treatment
- dependent diseases
- protein kinase
- kinase dependent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53822004P | 2004-01-22 | 2004-01-22 | |
PCT/EP2005/000602 WO2005070431A1 (en) | 2004-01-22 | 2005-01-21 | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507071A true BRPI0507071A (pt) | 2007-06-19 |
Family
ID=34807167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507071-6A BRPI0507071A (pt) | 2004-01-22 | 2005-01-21 | derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1708710A1 (ru) |
JP (1) | JP2007519662A (ru) |
KR (1) | KR20070009546A (ru) |
CN (1) | CN1909908A (ru) |
AR (1) | AR049769A1 (ru) |
AU (1) | AU2005205915B2 (ru) |
BR (1) | BRPI0507071A (ru) |
CA (1) | CA2552885A1 (ru) |
EC (1) | ECSP066718A (ru) |
IL (1) | IL176737A0 (ru) |
MA (1) | MA28400B1 (ru) |
NO (1) | NO20063758L (ru) |
PE (1) | PE20051089A1 (ru) |
RU (1) | RU2006130003A (ru) |
TN (1) | TNSN06226A1 (ru) |
TW (1) | TW200528103A (ru) |
WO (1) | WO2005070431A1 (ru) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
US7776865B2 (en) | 2005-10-06 | 2010-08-17 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
CN101360499B (zh) * | 2005-10-06 | 2015-10-07 | 默沙东公司 | 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途 |
US8114874B2 (en) | 2005-12-23 | 2012-02-14 | Ariad Pharmaceuticals, Inc. | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors |
AU2007223865A1 (en) * | 2006-03-08 | 2007-09-13 | Novartis Ag | Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |
WO2007109183A2 (en) * | 2006-03-20 | 2007-09-27 | Novartis Ag | Mutations and polymorphisms of fms-related tyrosine kinase 1 |
GB0606804D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic Compounds |
GB0606805D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
EP2074127A1 (en) * | 2006-09-28 | 2009-07-01 | Novartis AG | Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
EP1918291A1 (en) * | 2006-10-30 | 2008-05-07 | Novartis AG | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators |
WO2008153870A1 (en) * | 2007-06-07 | 2008-12-18 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
AU2010300925A1 (en) | 2009-09-30 | 2012-03-29 | Merck Sharp & Dohme Corp. | Novel compounds that are ERK inhibitors |
UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
WO2012020726A1 (ja) * | 2010-08-09 | 2012-02-16 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
WO2012023143A1 (en) | 2010-08-19 | 2012-02-23 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
US20150038500A1 (en) * | 2011-11-25 | 2015-02-05 | Catholic University Industry-Academic Cooperation Foundation | Pharmaceutical composition for preventing and treating ophthalmic disorders |
CN105906630B (zh) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物 |
HUE053067T2 (hu) | 2015-07-16 | 2021-06-28 | Array Biopharma Inc | Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
CN106588893A (zh) * | 2016-12-01 | 2017-04-26 | 北京万全德众医药生物技术有限公司 | 维拉佐酮双氧化物的制备 |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
CN118005640A (zh) * | 2018-01-29 | 2024-05-10 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
CN109836428A (zh) * | 2019-02-27 | 2019-06-04 | 华东师范大学 | 具有免疫抑制活性的吡唑[4,3-d]嘧啶衍生物及用途 |
WO2021007094A1 (en) * | 2019-07-10 | 2021-01-14 | Musc Foundation For Research Development | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury |
WO2021108408A1 (en) | 2019-11-25 | 2021-06-03 | Amgen Inc. | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
TW202337433A (zh) * | 2022-02-08 | 2023-10-01 | 美商德洛斯股份有限公司 | 用於治療癌症及其他適應症之組成物及方法 |
CN114751910B (zh) * | 2022-05-17 | 2023-02-24 | 重庆文理学院 | 一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3130633A1 (de) * | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
US5688949A (en) * | 1991-04-22 | 1997-11-18 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo 1,5-A!pyrimidine derivatives and anti-inflammatory agent containing the same |
CN1046730C (zh) * | 1994-06-21 | 1999-11-24 | 株式会社大塚制药工场 | 吡唑并[1,5-a]嘧啶衍生物 |
JP3163413B2 (ja) * | 1994-06-21 | 2001-05-08 | 株式会社大塚製薬工場 | 鎮痛剤 |
WO1998010590A1 (fr) * | 1996-09-02 | 1998-03-12 | Sony Corporation | Dispositif et procede de transmission d'un signal video |
AR041135A1 (es) * | 2002-09-04 | 2005-05-04 | Schering Corp | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas |
MXPA05002570A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
-
2005
- 2005-01-20 PE PE2005000080A patent/PE20051089A1/es not_active Application Discontinuation
- 2005-01-20 AR ARP050100208A patent/AR049769A1/es unknown
- 2005-01-21 KR KR1020067014683A patent/KR20070009546A/ko not_active Application Discontinuation
- 2005-01-21 BR BRPI0507071-6A patent/BRPI0507071A/pt not_active IP Right Cessation
- 2005-01-21 CN CNA2005800030379A patent/CN1909908A/zh active Pending
- 2005-01-21 EP EP05706961A patent/EP1708710A1/en not_active Withdrawn
- 2005-01-21 AU AU2005205915A patent/AU2005205915B2/en not_active Ceased
- 2005-01-21 CA CA002552885A patent/CA2552885A1/en not_active Abandoned
- 2005-01-21 WO PCT/EP2005/000602 patent/WO2005070431A1/en active Application Filing
- 2005-01-21 JP JP2006550056A patent/JP2007519662A/ja active Pending
- 2005-01-21 TW TW094101852A patent/TW200528103A/zh unknown
- 2005-01-21 RU RU2006130003/15A patent/RU2006130003A/ru not_active Application Discontinuation
-
2006
- 2006-07-06 IL IL176737A patent/IL176737A0/en unknown
- 2006-07-10 MA MA29182A patent/MA28400B1/fr unknown
- 2006-07-21 EC EC2006006718A patent/ECSP066718A/es unknown
- 2006-07-21 TN TNP2006000226A patent/TNSN06226A1/en unknown
- 2006-08-22 NO NO20063758A patent/NO20063758L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2552885A1 (en) | 2005-08-04 |
NO20063758L (no) | 2006-10-23 |
AU2005205915B2 (en) | 2009-05-21 |
JP2007519662A (ja) | 2007-07-19 |
ECSP066718A (es) | 2006-10-31 |
RU2006130003A (ru) | 2008-04-10 |
AR049769A1 (es) | 2006-09-06 |
TW200528103A (en) | 2005-09-01 |
MA28400B1 (fr) | 2007-01-02 |
KR20070009546A (ko) | 2007-01-18 |
TNSN06226A1 (en) | 2007-12-03 |
EP1708710A1 (en) | 2006-10-11 |
PE20051089A1 (es) | 2006-01-25 |
IL176737A0 (en) | 2006-10-31 |
AU2005205915A1 (en) | 2005-08-04 |
WO2005070431A1 (en) | 2005-08-04 |
CN1909908A (zh) | 2007-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507071A (pt) | derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase | |
BRPI0410563A (pt) | derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase | |
BR0315988A (pt) | Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos | |
BRPI0411868A (pt) | derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase | |
BRPI0507375A (pt) | derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase | |
WO2003070236A3 (en) | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | |
NO20072795L (no) | Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser | |
DK0836605T3 (da) | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling | |
BR112014027244A2 (pt) | derivados de benzamida para inibição da atividade de abl1, abl2 e bcr-abl1 | |
MX2007005644A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa. | |
MX2009006401A (es) | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. | |
BR0211807A (pt) | Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos | |
GB0211649D0 (en) | Organic compounds | |
BRPI0418179A (pt) | derivados de pirrolo[2,3-b] piridina ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas os compreendendo | |
BRPI0411863A (pt) | derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos | |
WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
MY143206A (en) | 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors | |
MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
BRPI0414488A (pt) | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina | |
BRPI0513287A (pt) | derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica | |
BR0312722A (pt) | Derivados de pirazol heterobicìclico como inibidores de qinase | |
TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
BRPI0508706A (pt) | derivados de dicloro-fenil-pirido[2,3-d]pirimidina inusitados, sua fabricação e uso como agentes farmacêuticos | |
TH94267A (th) | สารผสมเชิงเภสัชกรรมและวิธีการซึ่งใช้เทโมโซโลไมด์ และสารยับยั้งโปรตีนไคเนส |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |